Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and... see more

Recent & Breaking News (OTCPK:RGBP)

Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities

PR Newswire August 25, 2016

Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center

PR Newswire August 16, 2016

Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company

PR Newswire June 30, 2016

Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program

PR Newswire June 16, 2016

Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6

PR Newswire June 14, 2016

Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities

PR Newswire June 7, 2016

Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6

PR Newswire June 2, 2016

Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB

PR Newswire June 1, 2016

Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB

PR Newswire May 24, 2016

Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy

PR Newswire May 19, 2016

Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate

PR Newswire May 11, 2016

Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients

PR Newswire May 3, 2016

Regen BioPharma's HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study

PR Newswire April 28, 2016

Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK

PR Newswire April 21, 2016

Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy

PR Newswire March 23, 2016

Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint Inhibitor

PR Newswire February 24, 2016

Regen BioPharma, Inc.'s Immune Checkpoint Inhibitor Found to Stimulate Key Immune System Proteins Interleukin-17 and Interleukin-18

Press Releases February 17, 2016

Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors

PR Newswire February 3, 2016

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

PR Newswire January 26, 2016

Regen BioPharma, Inc. and the National Institutes of Health to Collaborate

PR Newswire January 20, 2016